OMNARIS

This brand name is authorized in Brazil, Canada, Hong Kong, Mexico, New Zealand, Singapore, United States

Active ingredients

The drug OMNARIS contains one active pharmaceutical ingredient (API):

1 Ciclesonide UNII S59502J185 - CICLESONIDE

Ciclesonide exhibits low binding affinity to the glucocorticoid-receptor. Once orally inhaled, ciclesonide is enzymatically converted in the lungs to the principal metabolite (C21-des-methylpropionyl-ciclesonide) which has a pronounced anti-inflammatory activity and is thus considered as the active metabolite. Read about Ciclesonide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OMNARIS Nasal spray	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R01AD13		R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501104701171319, 562620040000617
Country: CA	Health Products and Food Branch	Identifier(s): 02303671
Country: HK	Department of Health Drug Office	Identifier(s): 59322
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 128M2009
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 14526
Country: SG	Health Sciences Authority	Identifier(s): 13911P
Country: US	FDA, National Drug Code	Identifier(s): 70515-701